Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells.

BACKGROUND Vessel dilator and kaliuretic peptide have anticancer effects in human prostate adenocarcinomas. MATERIALS AND METHODS The effects of vessel dilator, kaliuretic peptide and cyclic GMP on Ras were examined in human prostate adenocarcinoma cells. RESULTS Vessel dilator and kaliuretic peptide decreased the activation of Ras -GTP over a concentration range of 0.01 microM to 1 microM. Vessel dilator and kaliuretic peptide (each 1 muM) inhibited the phosphorylation of Ras by 95% (p<0.0001) and 90% (p<0.0001), respectively. At 0.01 microM of kaliuretic peptide, the maximal inhibition was 95% . The inhibition of Ras lasted for 48 to 72 hours secondary to both peptides. Their ability to inhibit Ras was inhibited by cyclic GMP antibody and cyclic GMP itself inhibited Ras phosphorylation (89%; p=0.0015). CONCLUSION Vessel dilator and kaliuretic peptide both inhibit Ras partially mediated via cyclic GMP as part of their anticancer mechanism(s) of action.

[1]  Ying Sun,et al.  Cardiac Hormones Activate ERK 1/2 Kinases in Human Fibroblasts , 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[2]  J. Sebolt-Leopold,et al.  Advances in the Development of Cancer Therapeutics Directed against the RAS-Mitogen-Activated Protein Kinase Pathway , 2008, Clinical Cancer Research.

[3]  J. McCubrey,et al.  Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. , 2008, Current opinion in investigational drugs.

[4]  Ying Sun,et al.  Four cardiac hormones eliminate up to two-thirds of human breast cancers in athymic mice. , 2007, In vivo.

[5]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.

[6]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[7]  Ying Sun,et al.  Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. , 2007, In vivo.

[8]  Ying Sun,et al.  Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. , 2007, Anticancer research.

[9]  A. Alli,et al.  Four peptide hormones’ specific decrease (up to 97%) of human prostate carcinoma cells , 2005, European journal of clinical investigation.

[10]  J. Sebolt-Leopold,et al.  Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.

[11]  D. vesely,et al.  Signal transduction: activation of the guanylate cyclase-cyclic guanosine-3'-5' monophosphate system by hormones and free radicals. , 1997, The American journal of the medical sciences.

[12]  J. Bos,et al.  Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras , 1997, Oncogene.

[13]  Joyce Bos.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[14]  F. Murad,et al.  Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues. , 1984, The Journal of biological chemistry.

[15]  D. Paulson,et al.  Isolation of a human prostate carcinoma cell line (DU 145) , 1978, International journal of cancer.